Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft to a Buy rating on July 6, 2026. Quigley increased the price target for the stock from €55.00 to €62.50.
The upgrade follows a favorable US Supreme Court ruling regarding glyphosate litigation. This legal decision is expected to limit the company's long-term financial liabilities.
Separately, Bayer faces opposition from U.S. farm groups over proposed trade actions. The company requested federal duties on glyphosate imports from China, alleging the products are sold at artificially low prices.